49 research outputs found
PDB25 COST EFFECTIVENESS ANALYSIS OF HUMAN PREMIX INSULIN REGIMENS COMPARED WITH A PREMIX ANALOGUE INSULIN IN THE PRIVATE HEALTH CARE SECTOR IN SOUTH AFRICA
Get PDFPDB48 A RETROSPECTIVE ANALYSE OF THE IMPACT OF INCREASING BODY MASS INDEX ON MEDICAL RESOURCES FOR PEOPLE WITH TYPE 2 DIABETES IN UNITED STATES
Get PDFPDB20 COST-EFFECTIVENESS OF INSULIN DETEMIR VERSUS NPH FOR TYPE 1 DIABETES PATIENTS IN AN ITALIAN SETTING. A META-ANALYSIS
Get PDFEvidence Linking Hypoglycemic Events to an Increased Risk of Acute Cardiovascular Events in Patients With Type 2 Diabetes
Get PDFLast stage glaucoma in Germany: Costs and quality of life of patients from a Vision Rehabilitation Centre in Munich
No full textPDB48 A RETROSPECTIVE ANALYSE OF THE IMPACT OF INCREASING BODY MASS INDEX ON MEDICAL RESOURCES FOR PEOPLE WITH TYPE 2 DIABETES IN UNITED STATES
No full textPDB25 COST EFFECTIVENESS ANALYSIS OF HUMAN PREMIX INSULIN REGIMENS COMPARED WITH A PREMIX ANALOGUE INSULIN IN THE PRIVATE HEALTH CARE SECTOR IN SOUTH AFRICA
No full textPDB20 LONG-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN IN PATIENTS WITH TYPE 1 DIABETES USING A BASAL-BOLUS REGIMEN IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN
No full textPDB35 COST-UTILITY ANALYSIS OF BIPHASIC INSULIN ASPART VERSUS HUMAN INSULIN IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED IN TIER III HOSPITALS IN BEIJING, CHINA: A LONGTERM OUTCOMES MODEL EVALUATION FROM THE IMPROVE OBSERVATIONAL STUDY
No full textPDB7 LONGTERM HEALTH OUTCOMES IN NEWLY DIAGNOSED TREATMENT NAï VE TYPE 2 DIABETES PATIENTS INITIATED WITH BIPHASIC INSULIN ASPART IN CHINA: DATA FROM THE IMPROVE STUDY
No full text
